Azienda Ospedaliero-Universitaria di Modena
Quick facts
Marketed products
- Pain killer
- peritoneal dialysate at 37°C temperature · Nephrology
Peritoneal dialysate at 37°C facilitates the removal of uremic waste products and excess fluid from the blood across the peritoneal membrane during peritoneal dialysis. - Recombinant LH (Luveris) · Reproductive endocrinology; Fertility
Recombinant luteinizing hormone (LH) stimulates the ovaries to produce estrogen and progesterone, promoting follicle development and ovulation in women with LH deficiency.
Phase 3 pipeline
- No Treatment Added
No Treatment Added is a control arm representing standard care without an investigational therapeutic intervention.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Azienda Ospedaliero-Universitaria di Modena portfolio CI brief
- Azienda Ospedaliero-Universitaria di Modena pipeline updates RSS
Frequently asked questions about Azienda Ospedaliero-Universitaria di Modena
What are Azienda Ospedaliero-Universitaria di Modena's marketed drugs?
Top marketed products include Pain killer, peritoneal dialysate at 37°C temperature, Recombinant LH (Luveris).
What is Azienda Ospedaliero-Universitaria di Modena's pipeline?
Azienda Ospedaliero-Universitaria di Modena has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include No Treatment Added.
Related
- Pain killer
- peritoneal dialysate at 37°C temperature · Nephrology
- Recombinant LH (Luveris) · Reproductive endocrinology; Fertility
- Sector hub: All tracked pharma companies